Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

Summary

This phase II trial studies the side effects of acalabrutinib and rituximab and its effect in treating patients with previously untreated mantle cell lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that binds to a protein called CD20, which is found on B-cells, and may kill cancer cells. Giving acalabrutinib and rituximab may help to control mantle cell lymphoma in elderly patients.

Timeline

Start

2021-06-30

Primary completion

2026-08-30

Completion

2026-08-30

Drugs

Indications